A TRISPECIFIC ROR1 X CD3 T CELL ENGAGER MEDIATES IN VITRO TUMOR CELL KILLING AND IN VIVO TUMOR ERADICATION

被引：1

作者：

Chatterjee, Bithi ^{[1
]}

Snell, Daniel ^{[1
]}

Hess, Christian ^{[1
]}

Brock, Matthias ^{[1
]}

Spiga, Fabio ^{[1
]}

Simonin, Alexandre ^{[1
]}

Gunde, Tea ^{[1
]}

Warmuth, Stefan ^{[1
]}

Weinert, Christopher ^{[1
]}

Bassler, Nicole ^{[1
]}

Kirk, Niels ^{[1
]}

Schumacher, Nina ^{[1
]}

Mahler, Dana ^{[1
]}

Yaman, Yasemin ^{[1
]}

Bommer, Bettina ^{[1
]}

Gambino, Giorgio ^{[1
]}

Giezendanner, Noreen ^{[1
]}

Kuettner, Benjamin ^{[1
]}

Flueckiger, Naomi ^{[1
]}

Heiz, Robin ^{[1
]}

Wagen, Sandro ^{[1
]}

Diem, Dania ^{[1
]}

Zeberer, Julia ^{[1
]}

Urech, David ^{[1
]}

机构：

[1] Numab Therapeut, Wadenswil, Switzerland

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷

关键词：

D O I：

10.1136/jitc-2021-SITC2021.844

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

844

引用

页码：A885 / A885

页数：1

共 50 条

[1] Generation of a novel ROR1 x CD3 bispecific T-cell engager for better tumor killing and minimal cytokine release
Wu, Danqing
Gong, Shiyong
Wu, Xuan
Naren, Gaowa
Dong, Liqin
Lensky, Stephan
Wu, Chengbin
CANCER RESEARCH, 2024, 84 (07)
[2] A ROR1 SPECIFIC CD3 BISPECIFIC T-CELL ENGAGER ENGINEERED FOR SOLID TUMORS WITH AN EXPANDED THERAPEUTIC WINDOW
Rabinovich, Brian
Zhou, Xueyuan
Takimoto, Jeffrey
Song, Paul
Alici, Evren
Khanna, Nikhita
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1110 - A1110
[3] Local Activator and T Cell Engager (αBCMA x αPD-L1 x αCD3) with Enhanced Tumor Killing and Minimal Cytokine Release for the Treatment of Multiple Myeloma
Vrohlings, Melissa
Jungmichel, Stephanie
Mueller, Jan
Senn, David
Schleier, Thomas
Scheifele, Fabian
Wendelspiess, Severin
Leisner, Christian
Krauth, Maria-Theresa
Jaeger, Ulrich
Borras, Leonardo J.
BLOOD, 2020, 136
[4] Melanoma cells can be eliminated by sialylated CD43 x CD3 bispecific T cell engager formats in vitro and in vivo
de Jong, G.
Bartels, L.
Kedde, M.
Verdegaal, E. M. E.
Gillissen, M. A.
Levie, S. E.
Cercel, M. G.
van Hal-van Veen, S. E.
Fatmawati, C.
van de Berg, D.
Yasuda, E.
Claassen, Y. B.
Bakker, A. Q.
van der Burg, S. H.
Schotte, R.
Villaudy, J.
Spits, H.
Hazenberg, M. D.
van Helden, P. M.
Wagner, K.
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (06) : 1569 - 1581
[5] A novel bispecific T-cell engager for targeting ROR1 positive malignancies
Gohil, S. H.
Moscosso, S. R. Paredes
Harrasser, M.
Sorio, C.
Davidoff, A. M.
Nathwani, A. C.
Della Peruta, M.
HUMAN GENE THERAPY, 2016, 27 (11) : A60 - A60
[6] Antitumor activity of a ROR1 x CD3 bispecific antibody in non-small cell lung cancer
Wang, Yi
Zhang, Yuxi
Sun, Haoyi
Chen, Jilan
Yang, Hui
Zhong, Zhanqiong
Xiao, Xiaoqian
Li, Yanping
Tang, Yibei
Lu, Haolan
Tang, Xinzhi
Zhang, Mengyang
Wu, Wenjun
Zhou, Shiyi
Yang, Jiahui
INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 123
[7] Microenvironment-responsive anti-PD-L1 x CD3 bispecific T-cell engager for solid tumor immunotherapy
Liu, Dingkang
Bao, Lichen
Zhu, Haichao
Yue, Yali
Tian, Jing
Gao, Xiangdong
Yin, Jun
JOURNAL OF CONTROLLED RELEASE, 2023, 354 : 606 - 614
[8] Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy
Goebeler, Maria-Elisabeth
Bargou, Ralf
LEUKEMIA & LYMPHOMA, 2016, 57 (05) : 1021 - 1032
[9] A DLL3/CD3/CD137 trispecific T cell engager shows potent antitumor activity in small cell lung cancer models
Mikami, Hirofumi
Feng, Shu
Naoi, Sotaro
Azuma, Yumiko
Kayukawa, Yoko
Tsunenari, Toshiaki
Asanuma, Kentaro
Iwabuchi, Ryutaro
Nagano, Hiroaki
Shinozuka, Junko
Yamazaki, Masaki
Kuroi, Haruka
Gan, Siok Wan
Chichili, Priyanka
Shimizu, Shun
Matsuda, Yutaka
Ishii, Shinya
Kamikawaji, Shogo
Kinoshita, Yasuko
Shimizu, Yuichiro
Sakamoto, Akihisa
Muraoka, Masaru
Takahashi, Noriyuki
Kawa, Tatsuya
Shiraiwa, Hirotake
Kashima, Kenji
Mimoto, Futa
Kamata-Sakurai, Mika
Kitazawa, Takehisa
Igawa, Tomoyuki
CANCER RESEARCH, 2023, 83 (07)
[10] Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo
G. de Jong
L. Bartels
M. Kedde
E. M. E. Verdegaal
M. A. Gillissen
S. E. Levie
M. G. Cercel
S. E. van Hal-van Veen
C. Fatmawati
D. van de Berg
E. Yasuda
Y. B. Claassen
A. Q. Bakker
S. H. van der Burg
R. Schotte
J. Villaudy
H. Spits
M. D. Hazenberg
P. M. van Helden
K. Wagner
Cancer Immunology, Immunotherapy, 2021, 70 : 1569 - 1581

← 1 2 3 4 5 →